Medens den terminale eliminationshalveringstid og middel systemisk eksposition for palonosetron er øget hos patienter med svært nedsat leverfunktion, giver dette ikke anledning til dosisreduktion.
While the terminal elimination half-life and mean systemic exposure of palonosetron is increased in the subjects with severe hepatic impairment, this does not warrant dose reduction.